| Theme | Clinical research in the field of CKD-MBD | |
|---|---|---|
| Title | Clinical study on fibroblast growth factor 23 (FGF23) and αKlotho | |
| Publish Date | 2014/10 | |
| Author | Masatomo Taniguchi | Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University |
| [ Summary ] | Many clinical studies concerning FGF23 andα Klotho are outlined in this review. Furthermore, critical issues and prospects for these studies are discussed. A number of observation studies have suggested a close association between serum FGF23 concentration and the risks of mortality, cardiovascular disease, vascular calcification as well as CKD progression. However, the pathological effects of FGF23 remain to be determined. While a detection system to measure the soluble form of αKlotho has been developed, there have been a few clinical studies concerning the relationship between αKlotho and mortality or other clinical events. The physiological effects of endocrine αKlotho also remain to be defined. Further clinical or basic studies are required. | |